RxDoctor Payments Data

Lidia Bello, MD

General Practice · Deerfield Beach, FLNPI 1578145264

Payments from drug & device makers

$503in general payments, 2019–2025

Across 15 payments — averaging $33.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$186
  • Insulet Corporation$125
  • Boehringer Ingelheim$47
  • Lilly USA, LLC$43
  • Novo Nordisk$23
  • Johnson & Johnson$20
  • plus $59 from 4 others

What the payments were for

  • Food & beverage$503100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$503 in reported general payments places this provider in the 65th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$4,388
Medicare patients
19
Services billed
57

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin183$123,878
OzempicSemaglutide93$87,902
FarxigaDapagliflozin Propanediol122$83,442
EliquisApixaban93$71,733
LinzessLinaclotide83$45,823
JanuviaSitagliptin Phosphate39$22,586
ProliaDenosumab12$20,727
VascepaIcosapent Ethyl49$20,688
JanumetSitagliptin Phos/Metformin Hcl19$16,427
RybelsusSemaglutide15$14,291
MounjaroTirzepatide12$12,006
TrulicityDulaglutide12$11,284
MyrbetriqMirabegron18$9,941
EntrestoSacubitril/Valsartan14$9,394
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$47$123,878183 claims
Novo NordiskOzempic, Rybelsus$23$102,193108 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta$186$101,769170 claims
Lilly USA, LLCMounjaro, Trulicity$43$23,29024 claims
AmgenProlia$13$20,72712 claims
GSKTrelegy Ellipta$16$8,17413 claims
Johnson & JohnsonXarelto$20$7,02011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,901 general practice providers in Florida.

Other general practice in Deerfield Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →